Price$23.48-0.00 (-0.02%)
01:30 PM07:45 PM
News · 26 weeks68-83%
2025-12-142026-06-07
Mix4990d
- Other25(51%)
- SEC Filings16(33%)
- Insider6(12%)
- Analyst1(2%)
- Earnings1(2%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Assertio Holdings Inc.SCHEDULE 13G/A - Assertio Holdings, Inc. (0001808665) (Subject)
- SECSEC Form SC 14D9 filed by Assertio Holdings Inc.SC 14D9 - Assertio Holdings, Inc. (0001808665) (Subject)
- SECSEC Form SC14D9C filed by Assertio Holdings Inc.SC14D9C - Assertio Holdings, Inc. (0001808665) (Subject)
- SECSEC Form SC TO-C filed by Assertio Holdings Inc.SC TO-C - Assertio Holdings, Inc. (0001808665) (Subject)
- SECAssertio Holdings Inc. filed SEC Form 8-K: Other Events8-K - Assertio Holdings, Inc. (0001808665) (Filer)
- INSIDERDirector Mason Heather L gifted 6,666 shares and received a gift of 6,666 shares, decreasing direct ownership by 24% to 20,944 units (SEC Form 4)4 - Assertio Holdings, Inc. (0001808665) (Issuer)
- SECSEC Form SC14D9C filed by Assertio Holdings Inc.SC14D9C - Assertio Holdings, Inc. (0001808665) (Subject)
- SECSEC Form SC14D9C filed by Assertio Holdings Inc.SC14D9C - Assertio Holdings, Inc. (0001808665) (Subject)
- SECSEC Form SC TO-C filed by Assertio Holdings Inc.SC TO-C - Assertio Holdings, Inc. (0001808665) (Subject)
- SECAssertio Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Assertio Holdings, Inc. (0001808665) (Filer)
- PRAssertio to Be Acquired by Zydus Worldwide DMCC for $23.50 Per Share in CashAll-Cash Tender Offer of $23.50 per share or $166.4 Million Offer Represents 30.6% Premium to Original Agreement with Garda Therapeutics AND 75.8% Premium to Unaffected Price Assertio Holdings, Inc. (NASDAQ:ASRT) ("Assertio" or the "Company") today announced that, following an engagement process outlined under the revised merger agreement (the "Garda Merger Agreement") with Garda Therapeutics, Inc. ("Garda"), the Company's Board of Directors (the "Board") approved a definitive agreement with Zydus Worldwide DMCC, a subsidiary of Zydus Lifesciences Limited ("Zydus") to acquire all outstanding shares of Assertio common stock for $23.50 per share in cash, representing total consideration o
- SECSEC Form 10-Q filed by Assertio Holdings Inc.10-Q - Assertio Holdings, Inc. (0001808665) (Filer)
- SECSEC Form SC14D9C filed by Assertio Holdings Inc.SC14D9C - Assertio Holdings, Inc. (0001808665) (Subject)
- SECAssertio Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Assertio Holdings, Inc. (0001808665) (Filer)
- PRAssertio and Garda Mutually Agree to Delay Launch of Tender OfferAssertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), today announced that it has reached a mutual agreement with Garda Therapeutics, Inc. ("Garda") to delay the launch of the previously announced tender offer to acquire all outstanding shares of Assertio to May 14, 2026. As previously announced on May 4, 2026, Assertio has entered into an amended and restated merger agreement (the "Garda Agreement") to be acquired by Garda for $21.80 per share in cash, or total cash consideration of $153.2 million. The Company expects to file a Schedule 14D-9 in connection with the tender offer on May 14, 2026. In addition, Assertio will delay the launch of the previously announced tender
- SECAssertio Holdings Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Assertio Holdings, Inc. (0001808665) (Filer)
- INSIDERDirector Stark David Matthew was granted 4,851 shares, increasing direct ownership by 74% to 11,420 units (SEC Form 4)4 - Assertio Holdings, Inc. (0001808665) (Issuer)
- INSIDERDirector Emany Sravan Kumar was granted 4,851 shares, increasing direct ownership by 26% to 23,855 units (SEC Form 4)4 - Assertio Holdings, Inc. (0001808665) (Issuer)
- INSIDERDirector Kirk Sigurd was granted 4,851 shares, increasing direct ownership by 68% to 12,017 units (SEC Form 4)4 - Assertio Holdings, Inc. (0001808665) (Issuer)
- INSIDERDirector Mckee William was granted 4,851 shares, increasing direct ownership by 21% to 27,936 units (SEC Form 4)4 - Assertio Holdings, Inc. (0001808665) (Issuer)
- INSIDERDirector Mason Heather L was granted 4,851 shares, increasing direct ownership by 21% to 27,610 units (SEC Form 4)4 - Assertio Holdings, Inc. (0001808665) (Issuer)
- SECSEC Form SC14D9C filed by Assertio Holdings Inc.SC14D9C - Assertio Holdings, Inc. (0001808665) (Subject)
- SECAssertio Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Assertio Holdings, Inc. (0001808665) (Filer)
- PRAssertio and Garda Mutually Agree to Postpone Commencement of Tender OfferAssertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), today announced that it has reached a mutual agreement with Garda Therapeutics, Inc. ("Garda") to postpone the commencement of the previously announced tender offer to acquire all outstanding shares of Assertio to May 8, 2026. As previously announced on May 4, 2026, Assertio has entered into an amended and restated merger agreement (the "Garda Agreement") to be acquired by Garda for $21.80 per share in cash, or total cash consideration of $153.2 million. The Company expects to file a Schedule 14D-9 in connection with the tender offer on May 8, 2026. In addition, Assertio will postpone the commencement of the previously a
- SECSEC Form SC14D9C filed by Assertio Holdings Inc.SC14D9C - Assertio Holdings, Inc. (0001808665) (Subject)
ASRT FAQ
6 questionsWhat does Assertio Holdings Inc. do?
Assertio Holdings, Inc., a commercial pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. The company's pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; moderate to severe ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia...Where does ASRT stock trade?
Assertio Holdings Inc. (ASRT) is listed on NASDAQ.What sector and industry is ASRT in?
Assertio Holdings Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ASRT?
Assertio Holdings Inc. has had 4 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral with a $1800.00 price target on 2026-04-09.What companies are similar to ASRT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ASRT side-by-side with any of them on Quantisnow.How can I track ASRT on Quantisnow?
Quantisnow aggregates Assertio Holdings Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ASRT to receive live email and push alerts on every new disclosure.